Skip to content
Bored Studies
RecruitingPhase 3

Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

Novo Nordisk A/S · NCT07770841

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
450
US sites recruiting
15
Study start
August 12, 2026
Record last updated
September 9, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of this study is to see how oral semaglutide, when taken in lower doses help lowering of body weight in participants with excess body weight when compared to 'dummy' tablets (placebo). Results from this study will help select the most optimal lower dose of oral semaglutide that can be used for treating participants living with overweight or obesity.

Being studied: Semaglutide; Placebo

Conditions: Overweight; Obesity

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
  • Female or male (sex at birth).
  • Age 18 years or above at the time of signing the informed consent.
  • Body mass index (BMI) of
  • ≥ 27.0 kilogram per square meter (kg/m\^2) with the presence of at least one weight-related comorbidity including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or CV disease.

OR

  • ≥ 30.0 kg/m\^2.
  • History of at least one self-reported unsuccessful dietary effort to lose body weight.

Exclusion Criteria

  • A self-reported change in body weight greater than (>) 5% within 90 days before screening irrespective of medical records.
  • HbA1c ≥ 6.5% (48 millimoles per mole [mmol/mol]) as measured by the central laboratory at screening.
  • Consistent use of glucagon like peptide-1 (GLP-1) receptor agonists, including medication with glucagon like peptide-1 receptor agonist (GLP-1 RA) activity like dual GLP-1/gastric inhibitory peptide RAs, or amylin analogues before screening. Consistent use is defined as treatment.

Recruiting US locations

Study contacts (from the official record)

  • Novo Nordisk · (+1) 866-867-7178 · clinicaltrials@novonordisk.com
All weight loss studies in Alabama →
Research Study on How Well Oral Semaglutide Works for Weight Loss… (NCT07770841) | Bored Studies